A Phase II Whole Exome Sequencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Prostate cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms MATILDA

24 Jan 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
24 Jan 2023 Planned End Date changed from 1 Apr 2023 to 5 Dec 2024.
24 Jan 2023 Planned primary completion date changed from 1 Apr 2021 to 1 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com